aTyr Pharma (ATYR) Set to Announce Quarterly Earnings on Thursday

aTyr Pharma (NASDAQ:ATYR) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $2.50 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. On average, analysts expect aTyr Pharma to post ($0.44) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

aTyr Pharma Price Performance

Shares of NASDAQ:ATYR opened at $0.13 on Thursday. The business’s 50 day simple moving average is $0.35 and its 200-day simple moving average is $0.61. The firm has a market capitalization of $12.59 million, a price-to-earnings ratio of -0.21 and a beta of 0.91. aTyr Pharma has a 12 month low of $0.10 and a 12 month high of $1.11.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.